American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (1999) 20 357-364.10.1038/sj.npp.1395276

THA Improves Word Priming and Clonidine Enhances Fluency and Working Memory in Alzheimer's Disease

Paavo Riekkinen Jr MD, Ph.D and Minna Riekkinen MD, Ph.D
Department of Neuroscience and Neurology, University and University Hospital of Kuopio, Kuopio, Finlan

Correspondence: Dr Paavo Riekkinen, Dept. of Neuroscience and Neurology, University and University Hospital of Kuopio, Canthia Building, Kuopio, POB 1627, 70211, Finland

ABSTRACT

We investigated the effects of a single administration of a cholinesterase inhibitor, tetrahydroaminoacridine (THA, 25 and 50 mg, orally), and an alpha2-agonist, clonidine (0.5 and 2 mug/kg, orally), on neuropsychologic performance in two groups of patients with Alzheimer's disease (AD). Clonidine enhanced a spatial working memory and verbal fluency, but had no effect on spatial span or word priming. THA enhanced word priming, but had no effect on other performance measures. Our data suggests that degeneration of the LC noradrenergic system and the cholinergic cells of the basal forebrain have different functional consequences during the progression of AD. Finally, a combined treatment with noradrenergic and cholinergic drugs might produce a qualitatively broader effect on cognitive functions than either of the treatments alone, and more effectively attenuate clinical dementia.

Keywords: Frontal functions; Semantic Priming; Alzheimer's disease; alpha2-agonist; Cholinesterase inhibitor
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1999 by the American College of Neuropsychopharmacology